Oncotarget

Corrections:

Correction: MR imaging biomarkers evaluating vascular normalization window after anti-vessel treatment

PDF  |  How to cite

Oncotarget. 2022; 13:641-641. https://doi.org/10.18632/oncotarget.28217

Metrics: PDF 294 views  |   ?  

Jun Yang1, Chengde Liao1, Yifan Liu1, Guangjun Yang1, Tengfei Ke1, Yingying Ding1 and Qinqing Li1

1Department of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming 650118, Yunnan, P.R. China

Published: May 05, 2022

Copyright: © 2022 Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 4, panel ‘E’ contains an accidental duplication of panel ‘D’. The corrected Figure 4 (panels ‘D’ through ‘G’), is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2018; 9:11964–11976. DOI: https://doi.org/10.18632/oncotarget.22600

Figure 4

Figure 4: Microvessel density and pericyte coverage in C6 glioma. (D–G) Immunohistochemical analysis representative examples of tumors on day 4 after bevacizumab treatment showed that a low density of microvasculature (CD34) and highly covered with perivascular cells (SMA) in the treatment group (E and G) on day 4 compared with control group (D and F). Images were acquired at 200× (D, E) or 100× (F, G) magnification. Scale = 50 μm.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28217